MVEC has updated its respiratory syncytial virus (RSV) reference page to reflect the new National Immunisation Program (NIP) vaccine program.
From 3 February 2025, eligible pregnant women will be able to access the maternal RSV vaccine Abrysvo for free. The Australian Department of Health and Aged Care is also supporting national access to the monoclonal antibody Nirsevimab (brand name, Beyfortus) for newborns and young children at high risk of serious illness from RSV and where Abrysvo was not administered during pregnancy.
Read more about RSV and find links to helpful resources at MVEC: RSV.
Register for our CVU mini webinar on Wednesday 5 February for health professionals.